At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
PX-866drug
Likely dose
PX-866 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
In Brief
A Phase 2 clinical trial evaluating PX-866 for Glioblastoma. Completed, enrolled 34 participants across 7 sites.
Detailed Summary
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your glioblastoma multiforme.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesCanada
CollaboratorsCascadian Therapeutics Inc.
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartApr 2011
Primary CompletionOct 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedDec 14, 2010
Enrollment StartApr 1, 2011
Primary CompletionOct 29, 2014
Study CompletionFeb 13, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 15.5 years ago
Interventions
PX-866drug
1 cycle = 8 weeks on study PX-866 - 8mg PO Daily